YANTAI, China, Nov. 11, 2024 /PRNewswire/ -- As a company dedicated to social responsibility, Wanhua Chemical has consistently supported the communities in which it operates. This fall, Wanhua Chemical collaborated with downstream construction materials partners and local government agencies to launch a community care initiative aimed at enhancing living conditions for residents in affected areas. The initiative reflects Wanhua's commitment to not only business growth but also its role in creating positive social impact.
In recent months, Typhoon "Ma-on," the most powerful storm to hit northern Vietnam in nearly 30 years, left a trail of devastation, causing extensive economic losses and significant human impact. Many families in northern Vietnam have faced challenging living conditions and an urgent need for housing support. On October 2, Wanhua Chemical, together with its partners, responded by donating 3,300 square meters of PU roofing panels to several villages in Lao Cai province, including Xuan Thuong and Xuan Hoa. This donation was designed to help local residents rebuild and strengthen their homes, providing them with safer, more comfortable living environments. Local government representatives, who were actively involved in the coordination and distribution efforts, expressed deep appreciation for Wanhua's support. The local officials noted that this gesture of goodwill has not only provided practical help but has also strengthened the trust and recognition of Wanhua Chemical within the Vietnamese community.
Continuing its commitment, Wanhua Chemical and its partners made an additional donation on November 4, providing 1,260 square meters of PU roofing panels to assist seven households in Muong Hoa village, Sapa city. The donation was celebrated by local residents, and Sapa People's Committee Vice Chairman Quy Cao Ba praised Wanhua's generosity and dedication to the community. He emphasized that these materials have played a crucial role in community development and have helped foster a stronger bond of trust and cooperation between the company and the local population.
As a responsible corporate citizen, Wanhua Chemical is driven by the goal to be "an innovative, world-leading chemical company, admired by our employees and respected by the community." This initiative reflects Wanhua's commitment to social responsibility and is an essential part of the company's core values. Around the world, Wanhua employees are dedicated to contributing to the well-being and growth of local communities through actions that reflect compassion, responsibility, and sustainability.
Looking ahead, Wanhua Chemical will continue to monitor the needs of the Vietnam community. Staying true to its mission, "Advancing Chemistry, Transforming Lives," Wanhua is committed to working alongside partners to build a brighter future and create lasting positive change for communities worldwide.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Joining Hands to Build a Better Community - Wanhua Chemical's Support for Northern Vietnam
Joining Hands to Build a Better Community - Wanhua Chemical's Support for Northern Vietnam
ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across
North America, Asia, Europe and the Middle East
NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced today the successful completion of enrollment of the Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment (ALL-RISE) randomized controlled trial (RCT). This landmark study represents a significant milestone in the field of interventional cardiology, evaluating the clinical and economic benefits of the CathWorks FFRangio® System in diagnosing and treating coronary artery disease (CAD), offering potentially groundbreaking evidence that could redefine the standard of care.
The ALL-RISE Study included over 1,924 patients across 59 sites in North America, Asia, Europe and the Middle East. Participants presenting with coronary stenoses of intermediate significance and requiring physiology assessment were randomized to receive either FFRangio-guided treatment or invasive pressure wire-guided treatment. Notably, this was the first-ever randomized controlled trial in the United States to assess clinical outcomes using an angiography-based tool for physiologic lesion assessment.
In a joint statement, the ALL-RISE Study Chair, Dr. Ajay J. Kirtane (NewYork-Presbyterian/Columbia University Irving Medical Center) and Principal Investigators, Dr. William Fearon (Stanford University) and Dr. Allen Jeremias (St. Francis Hospital & Heart Center), stated, "On behalf of the study executive committee, we would like to congratulate and thank all the global investigators, study coordinators and patients who collectively enabled this incredible accomplishment. The high level of engagement and record speed of enrollment parallel the growing adoption of FFRangio globally. We look forward to sharing the results of this landmark study after clinical follow-up is completed."
CathWorks Sr. Director of Clinical Affairs, Alex Froimovich M.D., added, "The completion of ALL-RISE enrollment marks a significant milestone for our company and team's mission to transform how cardiovascular disease is diagnosed and treated. We believe this study, adding to FFRangio's growing body of clinical evidence, has the potential to significantly advance the field of coronary physiology and close the gap between its current adoption and the appropriate use guidelines recommendations. FFRangio has already demonstrated higher diagnostic accuracy over all other angio-based technologies, highlighting the fact that not all angio-based technologies are created equal, and therefore technology-specific clinical data are needed."
Cardiovascular disease (CVD) remains the leading cause of death in the United States. According to the American Heart Association's (AHA) 2024 Heart Disease and Stroke Statistics Update, CVD accounted for 931,578 deaths in the U.S. in 2021, and close to 18 million deaths globally. Coronary artery disease (CAD) is the single largest contributor, responsible for over 40% of CV deaths. CathWorks believes the results from the ALL-RISE study will build on what the company refers to as a new era in physiology, underscoring FFRangio as the new standard of care with the potential to drive better patient outcomes while delivering tangible economic and resource utilization benefits to healthcare systems.
ABOUT CATHWORKS
CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on LinkedIn.
Investors:
Mike Feher
mike.feher@cath.works
Media:
Sarita Monico
sarita.monico@cath.works
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial
